rYojbaba Co., Ltd. Common Shares (RYOJ) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] rYojbaba Co Ltd (RYOJ) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, this is a tiny Japan-based health care company newly listed on Nasdaq, and right now the stock looks more like a high-volatility trading story than a clean, proven compounding story. > **📍 Basic Profile** > > Market Cap **$0.06 billion** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$5.00** > **⚡ 3 Things You Should Know** > > 1. 📈 **Extreme volatility is the main story right now:** the stock jumped about 149% in a day, but it’s still far below its 52-week high of $11.43. In other words, price action is being driven more by momentum and trading flows than by steady business updates. > > 2. 💰 **The business is barely profitable on paper, but operating quality looks weak:** net margin is 3.9%, while operating margin is slightly negative at -0.72%. Basically, it suggests non-operating items may be helping reported earnings, which is not the kind of profit profile that gives a lot of comfort. > > 3. ⚠️ **Balance sheet liquidity looks okay, but earnings support is thin:** current ratio of 2.7 is healthy and debt-to-equity is low, yet negative interest coverage means operating earnings are not comfortably covering financing costs. So the company does not look financially distressed today, but it also doesn’t have much margin for error. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin 3.9%, operating margin negative | > | Growth Rate | Slow🐢 | 3-year revenue growth -3.8% | > | Financial Health | Moderate💛 | Debt-to-equity 0.69, current ratio 2.70 | > | Valuation | Pricey | PE 41.1x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** [Data unavailable] The company is classified under health care, but the provided data does not disclose its products, customers, or exact monetization model. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | [Data unavailable] | [Data unavailable] | [Data unavailable] | No segment disclosure provided | | [Data unavailable] | [Data unavailable] | [Data unavailable] | No segment disclosure provided | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 30.31% | Average | Suggests some product/service pricing power, but not unusually strong for health care | | Net Margin | 3.9% | Below Average | Thin bottom-line profits mean small shocks can wipe out earnings | | ROE | 12.14% | Average | Decent on the surface, but not strong enough by itself to offset weak operating margin | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | -3.8%* | [Data unavailable] | Slowing | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | \*Using 3-year revenue growth metric provided. **Growth Quality:** > What’s worth noting is that the growth picture is weak and incomplete. The available data shows revenue shrinking over a 3-year period, and there’s no earnings history here to prove the company is turning a corner. So if someone is buying the stock after the recent spike, they’re probably betting on a future improvement that is not yet clearly visible in the numbers provided. --- #### 💰 Financial Health Check **One Sentence:** This looks like a company with enough short-term cash cushion to pay the bills, but not enough operating earnings power to feel truly comfortable. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0.69x debt-to-equity | <60% safe | ⚠️High | | Current Ratio | 2.70 | >1.5 healthy | ✅Safe | | Cash Flow | [Data unavailable] | >0 | [Data unavailable] | **Extra context:** - Quick ratio of 2.52 is also solid, which usually means liquidity is not the immediate problem. - Long-term debt-to-equity of 0.51 is not alarming for a public company, but negative interest coverage of -6.30 is a real yellow flag because it means operating income is not covering interest expense. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.56 - 52-Week High: $11.43 - Current: $5.00, In the middle | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | ●(34.8% position) | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 41.1x | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE 41.1x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, a 41x trailing PE for a company with shrinking multi-year revenue and weak operating margin tells you the market is not valuing RYOJ for what it is today. It’s valuing it for some combination of turnaround, future growth, or trading scarcity. That can work in momentum phases, but it leaves very little room for disappointment. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-23 | Benzinga/ChartMill flagged RYOJ among health care after-hours and intraday movers | Neutral + Signals heavy trading interest, but not necessarily a change in fundamentals | | 2026-05-23 | Stock appeared in pre-market and gap-up mover lists | Neutral + Reinforces that recent attention is price-driven and momentum-led | | 2026-05-22 | Mentioned in after-market/pre-market mover screens | Neutral + Useful for traders, but not the same as business execution news | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 30.31% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 3.9% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 12.14% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | -3.8% | [Data unavailable] | [Data unavailable] | ↓ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Earnings Trend Interpretation:** [Data unavailable] There is no earnings history in the provided dataset, which matters because for a newly listed, highly volatile stock, consistency of execution is one of the first things you’d want to verify. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 0 firms | 0% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** [Data unavailable] > No insider transaction data was provided. For a small-cap recent IPO, insider selling or lock-up-related activity would be especially worth watching. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Volatility Risk:** Beta is 3.58 and the stock moved nearly 149% in a day → If this continues, the share price could swing wildly regardless of business fundamentals 2. **Earnings Quality Risk:** Net margin is positive, but operating margin and interest coverage are negative → If non-operating support fades, reported profitability could disappear quickly 3. **Information Risk:** The company IPO date is very recent and segment/earnings/analyst data are sparse → If disclosure remains limited, investors may be trading with an incomplete picture --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** RYOJ is a very small newly listed health care stock from Japan, and based on the data here, it’s still more of a speculative story than a clearly established operating business. > > **Key strength:** The main positive is that short-term liquidity looks fine, so this does not appear to be an immediate balance-sheet emergency. > > **Key risk:** The biggest concern is that valuation and price action look far ahead of current fundamentals, with weak operating profitability and shrinking multi-year revenue. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis